CA2909516C - Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones - Google Patents

Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones Download PDF

Info

Publication number
CA2909516C
CA2909516C CA2909516A CA2909516A CA2909516C CA 2909516 C CA2909516 C CA 2909516C CA 2909516 A CA2909516 A CA 2909516A CA 2909516 A CA2909516 A CA 2909516A CA 2909516 C CA2909516 C CA 2909516C
Authority
CA
Canada
Prior art keywords
protein
extract
isomerase
exogenous
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909516A
Other languages
English (en)
French (fr)
Other versions
CA2909516A1 (en
Inventor
Alice Yam
Dan Groff
Patrick RIVERS
Christopher D. Thanos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutro Biopharma Inc
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Publication of CA2909516A1 publication Critical patent/CA2909516A1/en
Application granted granted Critical
Publication of CA2909516C publication Critical patent/CA2909516C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2909516A 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones Active CA2909516C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361813914P 2013-04-19 2013-04-19
US61/813,914 2013-04-19
US201461937069P 2014-02-07 2014-02-07
US61/937,069 2014-02-07
PCT/US2014/034643 WO2014172631A2 (en) 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression

Publications (2)

Publication Number Publication Date
CA2909516A1 CA2909516A1 (en) 2014-10-23
CA2909516C true CA2909516C (en) 2023-03-07

Family

ID=50733442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909516A Active CA2909516C (en) 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones

Country Status (13)

Country Link
US (3) US10190145B2 (https=)
EP (1) EP2986731B1 (https=)
JP (2) JP6463732B2 (https=)
KR (1) KR102289258B1 (https=)
CN (1) CN105283556B (https=)
AU (1) AU2014253785B2 (https=)
CA (1) CA2909516C (https=)
DK (1) DK2986731T3 (https=)
ES (1) ES2922358T3 (https=)
HU (1) HUE059565T2 (https=)
IL (1) IL242148B (https=)
SG (2) SG10202108497TA (https=)
WO (1) WO2014172631A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909516C (en) 2013-04-19 2023-03-07 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
MX382952B (es) 2014-11-05 2025-03-13 Genentech Inc Métodos de producción de proteínas de cadena doble en bacterias.
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3234170A4 (en) * 2014-12-19 2018-07-25 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
KR20170122216A (ko) * 2015-03-06 2017-11-03 제넨테크, 인크. 초순수화 dsba 및 dsbc와 이를 제조하고 사용하는 방법
US20170029798A1 (en) * 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
CN105198983B (zh) * 2015-09-11 2018-11-06 中国石油大学(华东) 一种利于七次跨膜蛋白ccr5功能性表达的方法
CN106190940B (zh) * 2016-07-19 2019-06-14 北京三元基因药业股份有限公司 表达抗TNF抗体Fab片段的重组大肠杆菌工程菌
CN106399352B (zh) * 2016-11-09 2020-04-17 华东理工大学 调节目标蛋白表达的折叠因子及其应用
WO2018126287A1 (en) * 2016-12-30 2018-07-05 Ntxbio, Llc Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
US12227778B2 (en) 2016-12-30 2025-02-18 Nature's Toolbox, Inc. Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
US20200181670A1 (en) * 2017-08-11 2020-06-11 Synvitrobio, Inc. Improved In Vitro Transcription/Translation (TXTL) System and Use Thereof
WO2019127469A1 (zh) * 2017-12-29 2019-07-04 康码（上海）生物科技有限公司 一种高效的能源再生体系(bes)、试剂盒及其制备方法
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020096959A1 (en) * 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
ES2944837T3 (es) * 2018-11-08 2023-06-26 Sutro Biopharma Inc Cepas de E. coli con citoplasma oxidativo
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
WO2021091304A1 (ko) * 2019-11-08 2021-05-14 한국해양과학기술원 신규한 인간 상피세포성장인자-tf 융합 단백질 및 이의 용도
EP4114931A4 (en) * 2020-03-05 2024-05-01 Curie Co. Inc. METHODS FOR CELL PROTEIN EXPRESSION OF MATURE POLYPEPTIDES DERIVED FROM ZYMOGENS AND PROPROTEINS
CA3175683A1 (en) * 2020-04-29 2021-11-04 Xueyang FENG Compositions and methods for enhancing recombinant biosynthesis of cannabinoids
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
KR20220000028U (ko) 2020-06-29 2022-01-05 채인자 농작물용 농약 간편 분무장치
CA3192331A1 (en) 2020-09-14 2022-03-17 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
CN116555061A (zh) * 2022-01-28 2023-08-08 北京师范大学 一种酿酒酵母突变体及其在制备酒精中的应用
CA3255881A1 (en) * 2022-06-17 2023-12-21 Insitro, Inc. In situ sequencing of RNA transcripts with non-uniform 5' ends
CN115028691B (zh) * 2022-06-29 2024-09-10 青岛硕景生物科技有限公司 一种检测试纸用的独立质控系统、杂交瘤细胞株、质控线用包被单克隆抗体及其应用
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用ｉｌ－２綴合物之癌症療法
CN116925196B (zh) * 2023-06-08 2025-04-18 齐鲁工业大学(山东省科学院) 小分子热休克蛋白rsp_1572在提高宿主菌环境耐受性中的应用
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025218039A1 (zh) * 2024-04-16 2025-10-23 天津凯莱英生物科技有限公司 酶的高通量筛选方法及酶库的构建方法
CN118048325B (zh) * 2024-04-16 2024-07-16 天津凯莱英生物科技有限公司 酶的高通量筛选方法及酶库的构建方法
WO2025240255A1 (en) * 2024-05-11 2025-11-20 Biodiscovery, Llc Systems and methods of cell-free protein expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10145694A1 (de) * 2001-09-17 2003-04-03 Roche Diagnostics Gmbh Verfahren zur Erhöhung der Löslichkeit, der Expressionsrate und der Aktivität von Proteinen während der rekombinanten Herstellung
WO2004081033A2 (en) * 2003-03-11 2004-09-23 National Institutes Of Health Synthesis of proteins by cell-free protein expression
JP2005253432A (ja) * 2004-03-15 2005-09-22 Sekisui Chem Co Ltd タンパク質の生産方法、並びにそれに使用するための組成物、試薬及びキット
JP4561243B2 (ja) * 2004-08-27 2010-10-13 株式会社豊田中央研究所 無細胞タンパク質合成系のための媒体
DK2035554T3 (da) 2006-06-29 2013-06-17 Univ Leland Stanford Junior Celle-fri syntese af proteiner indeholdende ikke-naturlige aminosyrer
CA2673765A1 (en) * 2007-01-18 2008-07-24 The Board Of Trustees Of The Leland Stanford Junior University Enhanced cell-free synthesis of active proteins containing disulfide bonds
CN102348807B (zh) * 2009-01-12 2015-04-15 苏特罗生物制药公司 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
US20110136169A1 (en) * 2009-11-20 2011-06-09 Rutgers, The State University Of New Jersey Expression system compositions and methods
CN102732548A (zh) * 2012-05-16 2012-10-17 中国农业大学 一种表达蛇毒激肽原酶的高效麦胚无细胞蛋白合成系统的建立及应用
JP6421122B2 (ja) * 2012-10-12 2018-11-07 ストロ バイオファーマ， インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
CA2909516C (en) * 2013-04-19 2023-03-07 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones

Also Published As

Publication number Publication date
IL242148B (en) 2019-03-31
SG10202108497TA (en) 2021-09-29
HUE059565T2 (hu) 2022-11-28
AU2014253785A1 (en) 2015-11-05
US20210054429A1 (en) 2021-02-25
SG11201508642WA (en) 2015-11-27
HK1220993A1 (en) 2017-05-19
US20190161781A1 (en) 2019-05-30
CN105283556A (zh) 2016-01-27
DK2986731T3 (da) 2022-08-01
ES2922358T3 (es) 2022-09-13
JP2016518833A (ja) 2016-06-30
CA2909516A1 (en) 2014-10-23
US10774354B2 (en) 2020-09-15
WO2014172631A3 (en) 2014-12-18
WO2014172631A2 (en) 2014-10-23
WO2014172631A4 (en) 2015-02-19
AU2014253785B2 (en) 2018-07-19
JP6463732B2 (ja) 2019-02-06
KR102289258B1 (ko) 2021-08-11
EP2986731B1 (en) 2022-05-18
US20140315245A1 (en) 2014-10-23
CN105283556B (zh) 2020-07-14
KR20160002913A (ko) 2016-01-08
US10190145B2 (en) 2019-01-29
EP2986731A2 (en) 2016-02-24
JP2018157837A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
US10774354B2 (en) Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
US10487133B2 (en) Codon optimization for titer and fidelity improvement
CN101479379B (zh) 含有非天然氨基酸的蛋白质的无细胞合成
US12404512B2 (en) Method for optimizing antibody expression
US20200332280A1 (en) Use of lambda-gam protein in ribosomal display technology
TWI899326B (zh) 使用無細胞蛋白質合成系統來大規模生產抗體之方法
HK1220993B (en) Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
Terada et al. Cell-free protein production for structural biology
WO2005105994A1 (ja) ジスルフィド架橋形成型インビトロタンパク質合成方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190410

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250305

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250305

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303